News

A heartfelt Thank You and a Special Offer for our Global CRO Services Clients

DiscoveryBioMed, Inc. (DBM)has remained in business using a lab shift-based model and extra precautions through the entirety of this global health crisis since March 2020 and we continue to follow strict guidelines. We wanted to extend a quite heartfelt thank you to all of our CRO services clients which is growing and global clientele from across the US, Canada, multiple parts of the UK, multiple parts of the European Union, and Japan. Your continued patronage is very important to us, and the applied science we are doing to profile lead therapeutic assets for different human diseases and to screen for new ligands for different applied science indications is continually rewarding, fun and interesting We have added two new units during 2020. Our Sentirix unit is focused on the applied science use of human taste cell platforms for multiple industry sectors. Our TumorCube unit is focused on niche forms of human cancer where the cells are cultured and profiled as 3D organoid tissues as well as in traditional 2D formats. We continue deep efforts in our...

Read More

DiscoveryBioMed, Inc. Involved Actively in BIO Alabama Annual Conference, October 5-8

DiscoveryBioMed, Inc. (DBM) is honored and excited to be involved in the BIO Alabama Annual Conference to be held virtually from October 5-8. There are some great keynote speakers and sessions as well as a one-on-one partnering vehicle that DBM is co-sponsoring for the event. “At the BIO International Convention, DBM takes full advantage of the One on One Partnering vehicle to connect to future potential partners and clients,” explained Dr. Erik Schwiebert, CEO and CSO of DBM. “We encouraged a similar vehicle, given the virtual format for the meeting, where connections can be made and/or deepened across the BIO Alabama network and ecosystem.” In addition, Erik is joining Rachel Lane that leads a scientific writing enterprise called The Written Science for a fireside chat on small business grant programs at the NIH and NSF for life sciences and biotechnology companies. Erik is also going to connect virtually to the Auburn Engineering Club one evening that week to discuss the life sciences and biotechnology career path, DBM, and other topics of interest to Auburn undergraduates....

Read More

BIO ALABAMA-FIRESIDE CHAT WITH DR. ERIK SCHWIEBERT

We are pleased to announce our CEO and Chief Scientific Officer, Dr. Erik Schwiebert, will provide his expert insight into NIH vs NSF SBIR-STTR Programs in a Fireside Chat as part of this year’s BIO Alabama virtual conference. BIO Alabama is the leading advocate for Alabama's bioscience community. As the State affiliate of Biotechnology Innovation Organization, BIO Alabama represents the State regionally, nationally, and internationally by promoting the intellectual and innovative capital that make our state a premier place to invest, start, and grow in bioscience. This annual conference will include over 20 sessions and 40 speakers! Registration is open and we hope you will consider joining our annual conference. You can view the entire agenda and speaker roster here. We look forward to connecting with you virtually soon! Registration is open and we hope you will consider joining our annual conference.

Read More

TumorCube, a New Unit within DiscoveryBioMed, Will Use 3D Biogel-based Platforms to Perform 384-Well Plate-based Bioassays and 3D Bioreactor-driven Studies to Discover, Validate and Profile Anti-cancer Therapeutics on Human Cancer Cells

DiscoveryBioMed, Inc. (DBM, www.discoverybiomed.com) announces a new unit of its contract research organization (CRO) services business called TumorCube that is formed based upon our growing expertise in 3D Biogel-driven bioassays on diseased and normal human cell platform technologies. A trademark application has been filed. "DBM has a growing CRO services business in 3D Biogel-driven bioassays of diseased and normal human kidney cells. It is showcased prominently on our website, and we are proud to have many biotechnology companies and BioPharmaceutical organizations globally as our clients," explained Dr. Erik Schwiebert, Ph.D., CEO of DBM. "We have now extended those offerings to include the assay of human urological cancers and endocrine-driven cancers such as ovarian cancers and breast cancers." DBM is also assessing the feasibility of our 3D platforms for the assay of neurological and other cancers at present. DBM is utilizing existing human cancer cell lines in our initial technology optimization. "Interestingly, diseased human kidney cells and existing human cancer cell lines respond differently to specific lead therapeutic drugs or industry standard anti-cancer drugs when grown in...

Read More

Introducing SENTIRIX, a New CRO Unit of DiscoveryBioMed focused on Taste Profiling

SENTIRIX, a New DiscoveryBioMed Unit Working With Monell Center Licensed Technology, Will Implement Human Taste Bud Cell Platform Technologies as a Valuable Screening and Profiling Tool for the Food, Beverage, Flavor & BioPharmaceutical Marketplaces DiscoveryBioMed, Inc. (DBM, www.discoverybiomed.com) announces a new unit of its contract research organization (CRO) services business called Sentirix formed based upon our continuing 5-year collaboration with world-renowned, Philadelphia-based Monell Chemical Senses Center. "The name, Sentirix, is derived from the Latin word sentire ‘to feel in a sensory way,’" explained Dr. Erik Schwiebert, Ph.D., CEO of DBM. "Our logo showcases the name and illustrates a taste bud with a tastant molecule binding to the pore of the taste bud." A trademark application has been filed. Sentirix aims to provide the most relevant model of human taste sensory pathways for the purpose of understanding taste sensation, characterizing taste profiles of pharmaceuticals and food ingredients, and identifying naturally-derived taste modulators. Specifically, Sentirix uses human taste bud epithelial cell (hTBEC) platform technologies developed by DBM from the prior patented work of Drs. Hakan Ozdener and Nancy Rawson at Monell....

Read More

DiscoveryBioMed and Monell Chemical Senses Center Awarded $1.68 Million Small Business Grant to Profile Bitter Taste Blockers

Collaboration Will Screen Human Taste Bud Cells with Small Molecule Libraries to Develop Easier Ways for Children and Adults to Take Bitter-Tasting Medications (Birmingham, AL) - DiscoveryBioMed, Inc. (DBM) has been awarded nearly $1.7 million over the next two years by the National Institutes of Health’s Small Business Technology Transfer Research (STTR) program to find bitter taste blockers to improve medication compliance. This STTR award is administered by the National Institute on Deafness and Other Communication Disorders (NIDCD) within the National Institutes of Health. Philadelphia-based Monell Chemical Senses Center is a long-time DBM collaborator. The new funds continue their five-year relationship to advance Monell’s proprietary human taste-cell technology to discover taste modulators. Building on their successful creation of bitter-responsive human taste bud epithelial cell (hTBECs) lines with earlier funding, this industry-academic partnership’s Phase 2 STTR is aimed at discovering bitter blockers, small molecules combined with bitter medicines and bitter-tasting foods to improve their taste. “We are humbled and honored to receive this continued funding from NIDCD,” said Dr. Erik Schwiebert, CEO and CSO of DBM....

Read More